Lupin Ltd
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Lupin Ltd is navigating a transitional phase as it shifts towards a complexity-led portfolio, focusing on biosimilars and specialty drugs. Management's commentary highlights a robust pipeline and strategic investments in R&D, which are expected to drive long-term growth despite near-term challenges in the U.S. market due to increased competition for key products. Vista's financial outlook reflects moderated revenue growth and margin pressures, with a projected high-single-digit top-line growth and EBITDA margins around 25% for FY27. The company's strong performance in India, particularly in chronic therapies, supports its competitive position and market share. However, the anticipated decline in profitability from FY26-28 due to competitive intensity and pricing pressures in the U.S. market remains a watchpoint. Overall, Lupin's strategic focus on innovation and operational excellence positions it well for future growth, although execution risks related to regulatory approvals and market dynamics warrant close monitoring over the next 12-24 months
Why We Like This Stock
- Management's focus on a complexity-led portfolio is expected to enhance revenue growth and margins in the long term
- Strong performance in the Indian market, particularly in chronic therapies, supports Lupin's competitive position
- A robust pipeline of new product launches, including biosimilars and specialty drugs, positions the company for future growth
Things To Watch Out For
- Increased competition in the U.S. market for key products is expected to pressure margins and revenue growth
- Anticipated decline in profitability over FY26-28 due to competitive intensity and pricing pressures
- Execution risks related to regulatory approvals and market dynamics could impact the company's growth trajectory
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 20,011 | 22,708 | 27,958 | 30,568 | 33,712 |
| Profit Before Tax (Cr.) | 2,391 | 3,970 | 7,431 | 7,634 | 7,965 |
| PBT Margin | 11.9% | 17.5% | 2657.9% | 25.0% | 23.6% |
| Net Profit (Cr.) | 1,766 | 2,990 | 5,779 | 5,943 | 6,176 |
| Earnings Per Share | 38.2 | 64.9 | 125.9 | 129.5 | 135.1 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| BOB Capital Markets | ▲ Buy | 2,900 | 10-May-2026 |
| Bernstein | ▲ Buy | 2,707 | 22-May-2026 |
| CLSA | ▲ Buy | 2,690 | 11-May-2026 |
| Citigroup | ▲ Buy | 2,540 | 06-Jun-2026 |
| Deven Choksey | ▲ Buy | 2,280 | 14-May-2026 |
| Elara Capital | ► Accumulate | 2,447 | 23-Apr-2026 |
| Geojit Financials | ▲ Buy | 2,606 | 04-Jun-2026 |
| ICICI Securities | ▼ Reduce | 2,200 | 09-Aug-2026 |
| Macguire | ▲ Buy | 2,450 | 11-May-2026 |
| Morgan Stanley | ► Equalweight | 2,750 | 07-Aug-2026 |
| Motilal Oswal | ► Neutral | 2,500 | 08-Aug-2026 |
| Nomura | ▲ Buy | 2,580 | 11-May-2026 |
| Prabhudas Liladhar | ► Accumulate | 2,500 | 10-Aug-2026 |
Company Overview
Show Company Profile
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women's health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consists of labs and collection centers. The company has a strategic collaboration with TB Alliance for the development and commercialization of the investigational drug Telacebec for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.